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Ataxia telangiectasia is an autosomal recessive disease with a striking predisposition of lymphoid malignancies. ATM mutations have
been reported in adult sporadic lymphoma and leukaemia. The aim of this study was to investigate the possible involvement of the
ATM gene in the carcinogenesis of Hodgkin disease in children. Tumours were obtained from 23 patients and were subjected to
mutation screening and loss of heterozygosity analysis. Eight base substitutions were identified in seven patients. Of them, Y54Y, a
silent change, was observed in two patients and a known polymorphism, D1853N, in three patients. Of the other two patients, one
harboured a combined genotype P604S/F1463C, identified previously in two patients with Hodgkin lymphoma, and the other a novel
missense mutation, V595A. The alterations were present in the germ line, and both had a more aggressive disease. In all, 100 matched
normal ethnic controls were screened for these mutations and P604S/F1463C was identified in one healthy control. Loss of
heterozygosity was identified in four patients and in three of them it was located centromeric to the ATM gene, and, in one, it
spanned a large region, indicating the involvement of other tumour-suppressor genes in this disease. Missense variants of the ATM
gene are a rare event in childhood Hodgkin disease.
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Ataxia telangiectasia (A-T) is an autosomal recessive disorder
characterised by telangiectasia, progressive ataxia, pulmonary
infections, radiosensitivity and a combined immunodeficiency
(Shiloh, 1995). Ataxia telangiectasia patients show an increased
genomic instability, which results in translocations and inversions,
leading to 100-fold cancer excess, particularly lymphoid malig-
nancies (Morrell et al, 1986; Taylor et al, 1996). The most common
lymphoid neoplasms are non-Hodgkin lymphomas, followed by
acute lymphoblastic leukaemia and Hodgkin disease (5–10%)
(Hecht and Hecht, 1990).
The ATM gene is responsible for A-T, located on chromosome
11q22–23, and encodes for serine–threonine kinase belonging to
the phosphatidylinositol 3-kinase (PI3-K) family, and plays a central
role in signalling pathways activated by DNA damage (Savitsky et al,
1995a,b). Different studies identified a number of ATM targets
including c-abl, TP53, CHK-2, NBS1 and BRCA1 (Shiloh, 2003).
Ataxia telangiectasia heterozygotes have been suggested to have
a reduced life expectancy owing to a higher frequency of ischaemic
heart disease (Su and Swift, 2000) and an increased risk for cancer,
particularly for carcinoma of the breast (Swift et al, 1991; Broeks
et al, 2000; Olsen et al, 2001). Several studies have indicated that
ATM may also be involved in the development of some subtypes of
sporadic lymphoma and leukaemia. Missense and truncation
mutations in the ATM gene have been demonstrated in adult
leukaemias: T-cell prolymphocytic leukaemia (T-PLL) (Stilgen-
bauer et al, 1997; Vorechovsky et al, 1997; Stoppa-Lyonnet et al,
1998; Yuille et al, 1998), and B-cell chronic lymphocytic leukaemia
(B-CLL) (Bullrich et al, 1999; Schaffner et al, 1999; Stankovic et al,
1999; 2002). In adult lymphomas, Vorechovsky et al (1997) first
demonstrated two missense variants in 32 non-Hodgkin lympho-
mas. In addition, missense and loss-of-function mutations were
identified in mantle cell lymphoma (MCL), mainly associated with
11q22–23 loss of heterozygosity (LOH) (Stilgenbauer et al, 1999;
Schaffner et al, 2000; Camacho et al, 2002). ATM mutations have
been reported in diffuse large B-cell lymphoma (DLBCL) and
follicular lymphoma (FL) (Gronbaek et al, 2002). Recently, Offit
et al (2002) reported that ATM variants are rare in Hodgkin
lymphoma and in radiation-induced breast cancer after treatment
for Hodgkin disease.
The aim of the study was to investigate the possible involvement
of ATM gene in the pathogenesis of Hodgkin lymphoma in
children.
MATERIALS AND METHODS
A total of 23 children with Hodgkin’s disease participated in the
study that was approved by the ethics committee of the hospital.
Tumours were obtained from patients at diagnosis treated at the
Center for Pediatric Hematology Oncology, Schneider Children’s
Medical Center of Israel, between 1988 and 2001, and were snap-
frozen in liquid nitrogen. The cohort consisted of 13 male and 10
female patients, ranging in age from 4.5 to 17.5 years (median 13
years). The tumours were classified according to the criteria
established by Lukes and Butler (1966). The tumours belonged to
the histological subtypes as follows: 19 nodullar sclerosis (NS) and
four mixed cellularity (MC).
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Reagent (Molecular Research Center, Cincinnati, OH, USA),
according to the manufacturer’s instructions. Reverse transcrip-
tion (RT) was performed using random hexamers and ready-to-Go
RT–PCR beads (Amersham Biosciences, Piscataway, NJ, USA) for
nine overlapping fragments of the ATM gene, according to
instructions. Long SSCP analysis was performed on the RT–PCR
products, as previously described (Kukita et al, 1997). A suspected
sample was subjected to direct sequencing using the cycling
sequencing system (Applied Biosystems, Foster City, CA, USA)
and run on Perkin-Elmer ABI-377 automatic sequencer.
High molecular DNA was extracted from normal and tumour
tissues using standard procedures. An identified mutation was
verified on the tumour DNA and then on the normal DNA (PBL)
for the identification of a germ-line mutation.
Each specific missense mutation was screened in 100 matched
normal ethnic group: Ashkenazim or Arabs or non-Ashkenazim, a
total of 300 normal controls. The mutations were screened using
SSCP analysis for each of the three exons  13, 31 and 39.
Restriction analysis using SspI and MnlI was used for the
mutations in exons 5 and 14, respectively.
Loss of heterozygosity analysis was performed on 15 paired
tumour and blood DNA samples using four microsatellite markers.
Two markers were located within the 11q22–q23 locus (D11S1778,
D11S1817) and two in the ATM gene (NS22 and D11S2179).
RESULTS
Mutation analysis revealed eight alterations in seven out of 23
patients (30%) (Table 1). All of the alterations were base
substitutions, and in all cases the wild-type allele was preserved.
Normal tissue was available in all seven patients and their
normal DNA was screened for identified alterations. In all, the
alterations were present in the germ-line. The frequency of ATM
variants was analysed in samples of matched ethnic origin
(Table 1). Five patients were found to have two polymorphic
changes: Y54Y in exon 5 and D1853N in exon 39. Two patients of
Arab origin harboured the silent change Y54Y, which was observed
with similar frequency in the Hodgkin lymphoma patients and
matched ethnic controls, 0.04 and 0.03, respectively. D1853N was
observed in three patients of non-Ashkenazim origin, at an allele
frequency of 0.07 in our Hodgkin lymphoma patients and at a
frequency of 0.12 in the matched ethnic normal population.
The other alterations were P604S/F1463C in exons 14 and 31,
respectively. The P604S/F1463C combined genotype was identified
in one Hodgkin lymphoma of a mixed Ashkenazim/Iraqi origin
and in one of the control cases. The frequency of each allele
separately in the normal population was 0.015 and 0.02 for P604S
and F1463C, respectively. The novel mutation V595A was observed
in a Bedouin patient and in none out of 100 ethnic matched
controls.
Loss of heterozygosity analysis was performed on 15 paired
tumour and normal samples. In all, 12 patients were informative in
at least two markers and four (33%) exhibited LOH (Table 2). In
three patients, the region of LOH was located centromeric to the
ATM gene and, in one, the LOH spanned a large region, including
the markers centromeric and telomeric to the ATM gene. In
addition, two patients showed genomic instability in the NS22
marker, which is located in the ATM gene.
Three out of 23 patients were studied, relapsed, and in two of
them ATM missense alterations were identified. The patient
harbouring the combined genotype P604S/F1463C relapsed within
12 months after diagnosis and expired 7 months later. The other
patient, carrying the V595A alteration, relapsed twice, after 28
months and subsequently after additional 10 months, following
autologous bone marrow transplantation.
DISCUSSION
In this study, ATM missense variants were detected in two out of
23 (9%) childhood Hodgkin tumours. All alterations were present
in the germ-line. These two patients had a more aggressive clinical
course of the disease.
The P604S/F1463C genotype was reported previously in two
Hodgkin’s disease patients of Ashkenazi origin (Offit et al, 2002). It
is of note that our patient was of a mixed Ashkenazi/Iraqi origin.
Unfortunately, we were unable to determine the origin of the
mutation, as his parents were not available for analysis. The novel
mutation V595A was observed in a Bedouin patient who inherited
it from his mother, and was not identified in 100 matched normal
ethnic population.
In addition, we detected two polymorphic changes that have
been described in previous studies. Y54Y silent change was
described recently in an A-T patient who harboured two
truncation mutations (Buzin et al, 2003). D1853N is a well-
established known polymorphism that was observed at a similar
frequency in cancer patients and in controls reported in other
studies (Thorstenson et al, 2001; Offit et al, 2002).
Four out of 12 informative patients exhibited LOH centromeric
to ATM locus, and only in one patient LOH encompassed the
whole ATM region. Thus, LOH of the ATM gene is rarely involved
in childhood Hodgkin disease. In molecular and cytogenetic
studies of Hodgkin disease, loss of 11q was found to be a rare event
(Tilly et al, 1991; Dohner et al, 1992; Ohsima et al, 1999). In a
report utilising one marker telomeric to the ATM locus, three out
of seven Hodgkin patients exhibited LOH in the this region (Hasse
et al, 1999). All these observations may suggest that other tumour-
Table 1 ATM alterations in Hodgkin’s lymphoma tumours and matched
ethnic controls
Exon
Nucleotide
change
Amino-acid
change
(codon)
Frequency
a
Hodgkin’s
lymphoma
Frequency
controls
5 162T-C Y54Y 0.04 0.03
13 1784T-C V595A 0.02 0
14,31 1810C-T/4388T-G P604S/F1463C 0.02 0.003
39 5557G-A D1853N 0.07 0.12
aAllelic counts.
Table 2 LOH analysis of Hodgkin’s lymphoma tumors
Patient CEN
ATM gene
TEL
no. D11S1817 NS22 D11S2179 Genotype D11S1778
1 + + + D1853N7 +
2 – + + P604S/F1463C7 +
3+ + + +
4 LOH INS – Y54Y7 –
7–   – D1853N7 +
8– + + +
9 + + – D1853N7 –
10 + + –
11 – 7 ++
12 – + + Y54Y7 –
13 LOH INS – +
14 + - – –
15 LOH + + –
17 LOH LOH – LOH
18 – – + –
CEN¼centromeric; TEL¼telomeric;  : not informative; +: informative; LOH¼loss
of heterozygosity; INS¼microsatellite instability. 7 heterozygote.
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childhood Hodgkin’s disease.
No protein truncation mutations were identified in our child-
hood Hodgkin lymphoma tumours, similar to the absence of
truncation mutations reported in another study (Offit et al, 2002),
which included both adults and children. Moreover, no truncating
germ-line ATM mutations were detected in 52 survivors of
Hodgkin’s disease, adults and children, who developed secondary
neoplasms (Nichols et al, 1999).
In studies of ATM gene involvement in adult sporadic lymphoid
malignancies, missense and truncation mutations, both somatic
and germ-line origin, were identified. In T-PLL, missense
mutations clustered to the PI3-K region (Vorechovsky et al,
1997), while in B-CLL (Stankovic et al, 1999), MCL (Camacho et al,
2002) and DLBCL (Gronbaek et al, 2002) missense mutations
spread across the whole gene. Missense variants identified in
the present study were located outside the PI3-K region, similar
to results in the study by Offit et al (2002). The only alteration in a
known domain is the F1463C variant that resides in the
FAT region. In addition, the majority of cases of adult lymphoid
malignancies such as MCL and B-CLL show biallelic inactivation
of the ATM gene. It is different in children with ALL, in
whom single missense mutations with no LOH involvement
were reported (Pause et al, 2003). In our study of childhood
T-cell ALL, truncation and missense mutations were detected,
also without LOH involvement, and we could not identify
any genetic alteration in T-cell non-Hodgkin’s lymphoma (in
press). This could suggest a dominant-negative mechanism, as
was demonstrated by Scott et al (2002); some missense mutations
that reside outside the PI3-K region have an effect on ATM
downstream targets by a dominant-negative mechanism. In a more
recent study by Oguchi et al (2003), the dominant-negative effect
of a missense mutation located in the PI3-K domain was
demonstrated in a childhood acute leukaemia patient with MLL
rearrangement.
Our results indicate that missense variants of the ATM gene
occur in Hodgkin’s disease in children (9%), but at a low
frequency, and thus do not play a major role in the oncogenesis
of the disease in our childhood population in Israel. On the other
hand, observation of LOH outside the ATM locus may indicate the
involvement of other tumour-suppressor genes in this disease. The
presence of missense variants was associated with a more
aggressive disease, and further investigation of these substitutions
should clarify whether they have any functional effect on the
oncogenesis of Hodgkin lymphoma.
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